
About CHDR
_Document_BodyFEATURED CONTENT
-
Explore the landscape of dermatological drug development through a comprehensive framework for rational early-phase dermatological trials, centered around five foundational pillars.
-
The study investigates the potential of using smartphones and wearables to create objective biomarkers for mood disorders, specifically focusing on unipolar depression.
-
This study investigates the attitudes of cancer patients towards the adoption of mHealth technologies, including applications and wearable devices, for monitoring purposes during or after their treatment.
CONTACT INFORMATION
CHDR
Zernikedreef 8
Leiden, 2333 CL
NETHERLANDS
Phone: +31 715246430
Contact: Wouter ten Voorde
CHDR SOLUTIONS
-
Learn about a sophisticated suite of pharmacokinetic (PK) and pharmacometric services designed to accelerate and optimize early-phase drug development.
-
This essential guide walks through mastering the complex landscape of clinical trial regulations, providing a clear, practical breakdown of regulatory timelines, legal obligations, and more.
-
Explore a dynamic recruitment strategy being used to address the growing demand for participants in early-stage clinical trials while overcoming regulatory and ethical challenges.
-
Our dermatology studies provide results that are more than skin deep. Because the skin is the largest and most easily accessible organ, our dermatology research also facilitates drug development in other areas, including immunology and endocrinology. In addition, we are engaged in studying ways to improve wound healing.
-
NeuroCart is a fully self-contained, mobile CNS test battery developed in-house at CHDR, offering the possibility to measure a wide range of CNS effects in a pharmacological context.
-
With nearly three decades of successful application, NeuroCart remains a gold standard in CNS pharmacology, supporting precise, data-driven decisions in drug development.
-
Trial@home, CHDR’s dedicated strategy for off-site clinical trials, enables investigators to collect information as trial participants go about their day to day activities.